Barclays downgrades Phathom Pharmaceuticals (PHAT) with $14 target — how the stock has reacted to similar analyst actions
How PHAT has reacted before
| Report | Next-day move |
|---|---|
| Aug 14, 2026 | +3.7% |
| Jul 31, 2026 | +3.7% |
| Jul 30, 2026 | +3.7% |
| Dec 11, 2025 | +0.1% |
| Dec 08, 2025 | +2.2% |
| May 02, 2025 | -17.9% |
Median absolute move 3.7% · higher 5 of 6 · n=6
The call
- Firm: barclays
- Action: Downgrades
- Rating: Overweight
- Price target: 14.00
How $PHAT moves around analyst actions
| Date | Session move |
|---|---|
| Aug 14, 2026 | +3.7% |
| Jul 31, 2026 | +3.7% |
| Jul 30, 2026 | +3.7% |
| Dec 11, 2025 | +0.1% |
| Dec 08, 2025 | +2.2% |
| May 02, 2025 | -17.9% |
Base rates (n=6):
- Median absolute move: 3.7%
- Higher: 5 of 6
- Biggest up: +3.7%
- Biggest down: -17.9%